Cargando…
Time to achieve remission determines time to be in remission
INTRODUCTION: Though remission is currently a treatment goal in patients with rheumatoid arthritis (RA), the number of patients who achieve and sustain remission in daily practice is still small. It is suggested that early remission will be associated with sustainability of remission. The aim was to...
Autores principales: | Schipper, Lydia G, Fransen, Jaap, den Broeder, Alfons A, Van Riel, Piet LCM |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911884/ https://www.ncbi.nlm.nih.gov/pubmed/20487520 http://dx.doi.org/10.1186/ar3027 |
Ejemplares similares
-
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
por: Vermeer, Marloes, et al.
Publicado: (2013) -
DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis
por: van Riel, Piet LCM, et al.
Publicado: (2005) -
Outcome measures in inflammatory rheumatic diseases
por: Fransen, Jaap, et al.
Publicado: (2009) -
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
por: Vermeer, Marloes, et al.
Publicado: (2012) -
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)